Krenn Katharina, Klepetko Walter, Taghavi Shahrokh, Paulus Patrick, Aharinejad Seyedhossein
Laboratory for Cardiovascular Research, Center for Anatomy and Cell Biology, Medical University of Vienna, Waehringerstr. 13, A-1090 Vienna, Austria.
Eur J Cardiothorac Surg. 2007 Jul;32(1):35-41. doi: 10.1016/j.ejcts.2007.04.006. Epub 2007 May 3.
Vascular endothelial growth factor (VEGF) is the prime regulator of angiogenesis and vascular permeability and its serum levels increase in cystic fibrosis (CF). The mechanisms of VEGF overproduction and its impact on CF lung pathology and pulmonary vascular permeability during lung transplantation are not fully understood.
The expression of VEGF, its receptors, hypoxia inducible factor (HIF)-1alpha, beta, angiopoietins, and endothelial cell marker CD31 were studied in lung biopsies of CF and COPD patients and controls, using real time reverse transcription (RT)-PCR and Western blotting. DNA binding activity of HIF-1 to VEGF-A promoter was assessed by electrophoretic mobility shift assay (EMSA) and wet-to-dry lung weight ratios as well as microvascular density (MVD) were determined. Serum VEGF-A concentrations in enzyme-linked immunosorbent assay (ELISA) and wet-to-dry weight ratios of donor lungs were monitored during transplantation in CF and COPD patients. Primary graft dysfunction (PGD) was diagnosed and graded according to the guidelines of the International Society for Heart and Lung Transplantation.
VEGF-A165 and Flt-1 mRNA expression (P<0.05), VEGF-A (P<0.05), and HIF-1alpha (P<0.05) protein levels, DNA binding activity of HIF-1 to VEGF promoter (P<0.001) and extravascular lung water content (P<0.05) were increased in CF lungs versus controls, whereas MVD was unchanged. Before and during lung transplantation, VEGF-A serum concentrations were higher in CF versus COPD patients (P<0.05) and 60 min following reperfusion donor lungs transplanted to CF patients had higher tissue water contents than in COPD patients (P<0.05). PGD grade 3 occurred more frequently in CF (22.7%) versus COPD patients (4%). PGD grade 3 patients had significantly higher VEGF serum concentrations versus PGD grade 0-2 patients (P<0.001).
These data indicate that upregulated VEGF-A levels are most likely induced by enhanced HIF-1 binding to VEGF-A promoter, possibly contributing to elevated serum VEGF-A levels in CF. Furthermore, CF patients undergoing lung transplantation are possibly more susceptible to PGD because of increased VEGF-A expression that mediates increased lung graft vascular permeability.
血管内皮生长因子(VEGF)是血管生成和血管通透性的主要调节因子,其血清水平在囊性纤维化(CF)患者中升高。VEGF过度产生的机制及其对CF肺病理和肺移植期间肺血管通透性的影响尚未完全明确。
采用实时逆转录(RT)-PCR和蛋白质印迹法,研究CF、慢性阻塞性肺疾病(COPD)患者及对照组肺活检组织中VEGF及其受体、缺氧诱导因子(HIF)-1α、β、血管生成素和内皮细胞标志物CD31的表达。通过电泳迁移率变动分析(EMSA)评估HIF-1与VEGF-A启动子的DNA结合活性,并测定肺干湿重比以及微血管密度(MVD)。在CF和COPD患者移植过程中,采用酶联免疫吸附测定(ELISA)监测血清VEGF-A浓度,并监测供肺的干湿重比。根据国际心肺移植学会的指南诊断并分级原发性移植功能障碍(PGD)。
与对照组相比,CF患者肺组织中VEGF-A165和Flt-1 mRNA表达(P<0.05)、VEGF-A(P<0.05)和HIF-1α(P<0.05)蛋白水平、HIF-1与VEGF启动子的DNA结合活性(P<0.001)以及肺血管外含水量(P<0.05)均升高,而MVD无变化。在肺移植前及移植过程中,CF患者的VEGF-A血清浓度高于COPD患者(P<0.05),移植到CF患者的供肺在再灌注60分钟后组织含水量高于COPD患者(P<0.05)。CF患者中3级PGD的发生率(22.7%)高于COPD患者(4%)。3级PGD患者的VEGF血清浓度显著高于0-2级PGD患者(P<0.001)。
这些数据表明,VEGF-A水平上调很可能是由HIF-1与VEGF-A启动子结合增强所致,这可能是CF患者血清VEGF-A水平升高的原因。此外,由于VEGF-A表达增加介导肺移植血管通透性增加,接受肺移植的CF患者可能更容易发生PGD。